ReviewBiomedicines2026
From Risk Stratification to Prevention of Myocardial Infarction: Integrating Imaging and Biomarkers in the Perioperative Setting.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perioperative myocardial infarction (MI) and myocardial injury after noncardiac surgery (MINS) remain major causes of postoperative morbidity and mortality, yet optimal perioperative cardiovascular risk stratification remains challenging. This narrative review examines how cardiovascular imaging and circulating biomarkers may be integrated to improve perioperative risk assessment and to support more individualized preventive strategies in patients undergoing noncardiac surgery. We reviewed major clinical guidelines, landmark perioperative cohort studies, and key investigations addressing coronary computed tomography angiography, coronary calcium burden, natriuretic peptides, and cardiac troponin in the perioperative setting. Available evidence suggests that imaging and biomarkers provide complementary information, with imaging primarily reflecting structural coronary disease burden and biomarkers reflecting myocardial stress, biological vulnerability, and perioperative injury. Such multimodal assessment may refine risk estimation beyond conventional clinical indices alone, particularly in selected intermediate-risk patients or those with uncertain functional capacity. However, important limitations remain. Current evidence is heterogeneous across study populations, testing strategies, and endpoints, and standardized pathways for integrating imaging and biomarkers into routine clinical decision-making are not yet established. In addition, cost-effectiveness, accessibility, and the extent to which improved risk discrimination translates into better perioperative outcomes remain uncertain. Overall, the integration of imaging and biomarkers offers a clinically relevant framework for moving from perioperative risk stratification toward prevention, but its practical implementation and outcome benefit require further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.